# Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers

> **NCT02589795** · PHASE1 · COMPLETED · sponsor: **Imperial College London** · enrollment: 28 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** DNA-C CN54ENV
- **BIOLOGICAL:** CN54gp140
- **DEVICE:** Trigrid Delivery System - Intramuscular
- **DEVICE:** Trigrid Delivery System - Intradermal

## Key facts

- **NCT ID:** NCT02589795
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-11
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589795, "Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02589795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*